An interventional study of Collagen membrane over BMAC/bovine graft in sinus lift and PRF membrane over BMAC/bovine graft in sinus lift in Bone Loss, Alveolar, sponsored by Cairo University. Recruiting at 1 site in Egypt. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-08-14.
Sponsored by Cairo University · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 30 studies in Alveolar Bone Loss by Cairo University — 10 open to participants now, 11 under way, none of them phase 3. Alveolar Bone Loss · Cairo University.
Among the 30 studies in Alveolar Bone Loss by Cairo University, this one is the 30th largest by planned enrollment, is one of 2 that started in 2023, is one of 29 with no phase, reaches primary completion later than 0 of the 10 other live ones, and was the 17th registered.
320 studies on the registry are indexed under Alveolar Bone Loss; 79 are open to participants now.
Browse Alveolar Bone Loss studies →10 of the 30 studies in Alveolar Bone Loss by Cairo University are open now, in 1 country. Recruiting first, the newest first:
Cairo University · Sites in Egypt
Ages 20–70 · Healthy volunteers
Cairo University · Sites in Egypt
Ages 20–60
Cairo University · Sites in Egypt
Ages 20–70 · Healthy volunteers
Cairo University · Sites in Egypt
Ages 18+ · Healthy volunteers
Cairo University · Sites in Egypt
Ages 18+ · Healthy volunteers
By country, each count listing its studies:
Of the 47 Alveolar Bone Loss studies recruiting now, 19 (40%) set no upper age limit and 22 (47%) stop at 75 or younger; 4 take children under 18; 24 take healthy volunteers.
This study: 18 Years to 60 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
30 studies; the count open now beside each. This study's row is marked.
First in 2016; this study’s year is marked. 2 started in 2023.
This study's planned enrollment of 2 is below the median of 25 across 271 interventional studies indexed under Alveolar Bone Loss.
Median enrollment 20 across the 30 interventional studies. Of the 7 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Cairo University is the lead sponsor of 4,967 studies on the registry; 1,474 are open to participants now.
Of its 37 completed or terminated interventional studies of FDA-regulated products, 5 (14%) have results posted.
2 of the studies in Alveolar Bone Loss by Cairo University that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07475507Cairo UniversityEffect of PEEK and Titanium Framework Reinforcement on Marginal Bone Loss Around Implants Supporting a Fixed All-on-four Prosthesis in Completely Edentulous Mandibles | 2026-12 |
| NCT07701473Cairo UniversityNovel Synthetic Membrane for Horizontal Bone Augmentation: A Case Series | 2027-03-01 |
Add all 2 to your calendar (.ics) → With an account.
Among the 30 studies in Alveolar Bone Loss by Cairo University, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Utilization of collagen vs PRF membrane over the graft following sinus lift procedure and before suturing
Assessment of the effect of membrane overlying bone marrow aspirate concentrate - bovine graft mixture in sinus lift procedure
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Collagen membrane will be used to BMAC loaded on bovine graft . Variables include assessment of the osteogenic potential In terms of bone density measurements of graft immediate and 4 months Postoperative
Procedure: Collagen membrane over BMAC/bovine graft in sinus lift
Platelet rich fibrin membrane will be used to BMAC loaded on bovine graft . Variables include assessment of the osteogenic potential In terms of bone density measurements of graft immediate and 4 months Postoperative
Procedure: PRF membrane over BMAC/bovine graft in sinus lift
Collagen membrane to cover BMAC/bovine graft in sinus lift and evaluation of its effect on osteogenic potential of BMAC in sinus lift procedure
PRF membrane to cover BMAC/bovine graft in sinus lift and evaluation of its effect on osteogenic potential of BMAC in sinus lift procedure
Radiographic Bone density assessment
Bone density measurements on Cone beam CT/CBCT immediate and 4 months radiographic density measurements in haunsfield units, immediate and 4 months postoperative
Time frame: 4 months ( immediate - 4 months postoperative)
Radiographic Bone height assessment
Assessment of bone hight on CBCT, mmediate and at 4 months postoperative
Time frame: 4 months ( immediate - 4 months postoperative)
Started Jan 2023 (actual). Primary completion is estimated for Aug 2023, 7 months after the start.
Of 169 non-industry interventional studies with no phase under Alveolar Bone Loss, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 30. This study's planned 7 months is below that.
Counting every sponsor, half of 169 studies reached it within 18 months; a quarter within 11 and three quarters within 30.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.